AtCor Medical (ASX: ACG),
the developer and marketer of the SphygmoCor(R) system, which
measures central blood pressures and arterial stiffness
noninvasively, today announced that a new study* funded by the
National Institutes of Health (NIH) found that when patients’ central
pulse pressures exceeded 50 mm of mercury, there was a significant
increase in cardiovascular events. The 2,405 patient study was
presented on November 12 at the 2008 American Heart Association
Buy generic lexapro Scientific Sessions in New Orleans.
Central pulse pressure, the difference between systolic and diastolic
blood pressure in the ascending aorta, was measured noninvasively in
the study using AtCor Medical’s SphygmoCor technology. While central
blood pressure has consistently been shown to be a more powerful
predictor of cardiovascular events than traditional cuff blood
pressure measurements taken at the arm, this study is the first to
show a specific threshold value for central pressure, above which
risk is significantly increased. No similar threshold was identified
for brachial cuff blood pressure. This is the most powerful evidence
to date related to a specific treatment target for central pressures,
which can be managed by vasoactive hypertension drugs as well as, in
some cases, lifestyle changes.
Central pulse pressure as a treatment target
Study participants were initially free of cardiovascular disease and
were followed for a period of 5.5 years. During the course of the
study, over 340 participants experienced a major cardiovascular
event. The study abstract concluded that central pulse pressure
equal to or greater than 50 mm of mercury predicts adverse
cardiovascular outcomes independent of other risk factors for
cardiovascular disease. It further stated that these findings call
for examination of noninvasive central pulse pressure as a treatment
target in clinical intervention strategies.
"This is a major development," said Duncan Ross, AtCor Medical’s
President and CEO. "Many studies have shown that elevated central
blood pressure is associated with increased incidence of heart
attack, stroke and kidney disease. This research identifies a
specific central blood pressure threshold where events sharply
increase — identifying patients at risk who would not be identified
with standard cuff blood pressure measurements taken at the arm. The
data from this study will be vitally important to clinicians in
diagnosis and drug therapy management — and in pharmaceutical
trials."
About AtCor Medical
AtCor Medical develops and markets products for the early detection
of cardiovascular risk and management of cardiovascular disease. Its
technology allows researchers and clinicians to measure central blood
pressure noninvasively. The company’s SphygmoCor system visibly
identifies the effects of reflected blood pressure in the central
aortic pressure wave, effects which cannot be detected with standard
blood pressure monitoring. More than 1,700 SphygmoCor systems are
currently in use worldwide at major medical centers, research
institutions and in various clinical trials with leading
pharmaceutical companies. The company’s technology has been featured
in over 400 peer-reviewed studies published in leading medical
journals. AtCor has operations in Australia, the United States and
Europe.
*Mary J. Roman et al.
Central Pulse Pressure 50mmHg Predicts Adverse Cardiovascular Outcome: The Strong Heart Study Circulation. 2008;118:S_1157
AtCor Medical
Generic ultram pills no prescription | Buy propecia without prescription | Buy clomid pills
April 29th 2008 Uncategorized
